Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987109 | 1.00 | USP2 (0.42) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL14987412 | 1.00 | USP2 (0.42) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL15042289 | 0.91 | KDM4E (0.36) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL12908141 | 0.91 | KDM4E (0.36) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL13809524 | 0.91 | KDM4E (0.36) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL8624823 | 0.88 | KDM4E (0.37) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL25144268 | 0.86 | KDM4E (0.36) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL30210790 | 0.85 | KDM4E (0.32) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL30210365 | 0.85 | KDM4E (0.39) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL23378606 | 0.84 | USP2 (0.34) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | CNR2, CNR1, OPRK1 | USP2 1185/4885TSHR 1128/4885KDM4E 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.